6 O
ADVERSE O
REACTIONS O
EXCERPT O
: O
The O
most O
common O
adverse O
reactions O
( O
incidence O
< O
1 O
% O
) O
are O
injection O
site O
irritation O
and/or O
pain O
. O

( O
6.1 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Navidea O
Biopharmaceuticals O
, O
Inc O
. O
at O
1-800-476-5270 O
or O
www.lymphoseek.com O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

In O
open O
label O
, O
single O
arm O
clinical O
trials O
, O
553 O
patients O
with O
either O
breast B-Not_AE_Candidate
cancer I-Not_AE_Candidate
, O
malanoma B-Not_AE_Candidate
, O
or O
squamous B-Not_AE_Candidate
cell I-Not_AE_Candidate
carcinoma I-Not_AE_Candidate
of I-Not_AE_Candidate
the I-Not_AE_Candidate
oral I-Not_AE_Candidate
cavity I-Not_AE_Candidate
, O
skin O
, O
and O
lip O
received O
Lymphoseek O
. O

No O
patients O
experienced O
serious O
adverse O
reactions O
. O

Injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
irritation I-OSE_Labeled_AE
( O
4 O
patients O
; O
0.7 O
% O
) O
and O
pain O
( O
1 O
patient O
; O
0.2 O
% O
) O
were O
reported O
. O

